All In Biotech

Drug Trial Radar · NCT01807923

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Last checked: Nov 19, 2026Latest source record: Aug 31, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 559 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

559

Actual

Start

May 2013

Primary completion

Apr 2014

Study completion Apr 2014

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Mar 8, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study was to evaluate the efficacy of lumacaftor in combination with ivacaftor at Week 24 in participants aged 12 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene.

Conditions

  • Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Interventions

  • Lumacaftor Plus Ivacaftor CombinationDrug

    Fixed dose combination tablet

  • IvacaftorDrug

    Film-coated tablet

  • PlaceboDrug

    Matching placebo tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 24Time frame: Baseline, Week 16 and 24

Locations

89 sites in 11 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Anchorage, Alaska

  • Site not named

    Tucson, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Fresno, California

  • Site not named

    La Jolla, California

  • Site not named

    Loma Linda, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Madera, California

  • Site not named

    Oakland, California

  • Site not named

    Palo Alto, California

  • Site not named

    Denver, Colorado

  • Site not named

    Gainsville, Florida

  • Site not named

    Hollywood, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Boise, Idaho

  • Site not named

    Chicago, Illinois

  • Site not named

    Park Ridge, Illinois

  • Site not named

    Peoria, Illinois

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Kansas City, Missouri

  • Site not named

    Bedford, New Hampshire

  • Site not named

    Lebanon, New Hampshire

  • Site not named

    Long Branch, New Jersey

  • Site not named

    Hawthorne, New York

  • Site not named

    New York, New York

  • Site not named

    Valhalla, New York

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    Durham, North Carolina

  • Site not named

    Akron, Ohio

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Dayton, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Hershey, Pennsylvania

  • Site not named

    Knoxville, Tennessee

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.